The International Collaboration on Cosmetics Safety enters a new chapter with the appointment of its 2026 Board officers, reinforcing its global commitment to advancing animal-free approaches in cosmetics safety science at a time of rapid regulatory and scientific change.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its 2026 Board officers after elections held during the organization’s December 2025 Board meeting, a milestone that underscores how this relatively young global initiative is solidifying its position in promoting scientifically robust, human‑relevant alternatives to animal testing in cosmetics safety assessment. The newly selected leadership reflects continuity as well as the organization’s growing sophistication, building on a year of significant accomplishments while positioning itself to expand its impact across regulatory, scientific, and industry communities worldwide.
ICCS operates at the intersection of science, policy, and collective engagement, bringing together a wide spectrum of stakeholders who pursue a common goal: promoting the global acceptance and implementation of animal-free safety science for cosmetics and their ingredients. The designation of the 2026 Board officers underscores the organization’s dedication to maintaining a strategic direction while adapting to an increasingly complex international landscape, where expectations related to ethical research, scientific rigor, and regulatory alignment continue to evolve.
Continued leadership stability and expansive global representation
The 2026 Board leadership brings together senior figures from across the cosmetics, consumer products, and regulatory advocacy sectors, reflecting the multi-stakeholder nature that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been re-elected as Chair of the Board of Directors. His reappointment signals confidence in a leadership approach that has emphasized scientific credibility, global cooperation, and constructive engagement with regulators.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose long-standing work in industry advocacy and regulatory engagement offers a valuable blend of regional insight and policy expertise. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing extensive knowledge of regulatory toxicology and international product safety systems. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing significant leadership experience in toxicology and organizational governance.
Together, the officers constitute a leadership team whose background extends across multinational corporations, industry groups, and regulatory science, thereby strengthening ICCS’ role as a neutral forum for collaboration rather than a promoter of any individual sector. This equilibrium remains essential to the organization’s credibility, especially as it aims to shape regulatory perspectives and foster alignment on animal-free safety approaches.
Driving progress in animal-free science through collective collaboration
At the heart of ICCS’ mission is the belief that animal-free approaches to safety assessment are not only ethically preferable but scientifically superior when properly developed and validated. Since its formation in early 2023, ICCS has worked to demonstrate that non-animal methods can provide reliable, relevant information for protecting both human health and the environment. The confirmation of the 2026 Board officers comes at a moment when this message is gaining traction, supported by tangible outputs and growing engagement from regulators around the world.
Throughout 2025, ICCS rolled out multiple initiatives that strengthened its scientific foundation while extending its overall impact. Among these, it released a Best Practice Guidance document designed to bring greater clarity and consistency to the application of animal‑free safety assessment approaches. This resource aimed to bridge the divide between scientific advances and regulatory expectations, offering a practical tool that stakeholders could rely on when producing or evaluating non‑animal data.
In parallel, ICCS supported the development of new methodologies aligned with next generation risk assessment (NGRA), an evolving paradigm that integrates advanced in vitro, in silico, and exposure-based approaches. These methodologies are increasingly viewed as essential to modern toxicology, offering the potential for more human-relevant insights while reducing reliance on animal testing. ICCS’ involvement in this space reflects its commitment to advancing not only ethical outcomes but also scientific excellence.
ICCS has also placed strong importance on open dialogue, and throughout 2025 the organization engaged widely with regulators, scientists, and policymakers in various regions, helping shape conversations about how animal-free data can be interpreted and integrated into current regulatory systems, a series of exchanges that has significantly advanced mutual understanding and confidence, especially in regions where the approval of non-animal approaches is still evolving.
A pivotal moment for cosmetics safety regulation
The installation of the 2026 Board officers takes place during a phase marked by notable transformations in global cosmetics regulations, as many markets reassess long‑standing testing standards in response to public expectations, scientific advancements, and new international policy trends, and within this shifting environment, organizations like ICCS remain vital in aligning innovation with regulatory requirements to ensure that progress continues to be both reliable and sustainable.
ICCS leadership has long underscored that moving toward animal‑free safety science cannot progress through isolated initiatives; rather, it demands synchronized engagement from industry, academia, regulatory bodies, and civil society. The Board’s makeup embodies this principle by uniting figures who grasp the technical, regulatory, and organizational aspects required to drive meaningful transformation.
ICCS leadership statements after the elections conveyed a blend of confidence and pragmatism. They noted the progress achieved in recent years while recognizing that substantial challenges persist. Securing broad regulatory endorsement for animal-free methodologies will demand sustained research investment, open data dissemination, and continuous collaboration with authorities to respond to valid concerns about reliability, real-world relevance, and safeguarding public health.
The re-elected Chair emphasized the vital need to rely on ICCS’ global, multi-stakeholder framework to close the gap between innovation and regulation, ensuring that advances in animal-free science extend beyond the laboratory and evolve into dependable, consistently implemented tools that regulators can trust.
Strengthening the foundation for enduring influence
As ICCS looks toward 2026 and the years to follow, the organization stays dedicated to expanding its impact while reinforcing its achievements. The newly appointed Board leadership is anticipated to play a central role in shaping priorities that blend scientific ambition with practical implementation. This includes identifying fields that need additional direction or agreement, advancing the validation and spread of new methodologies, and promoting global harmonization to reduce inconsistencies in regulatory expectations.
Education remains another key pillar of ICCS’ strategy. By providing accessible, science-based resources and forums for discussion, the organization aims to demystify animal-free safety science and encourage informed decision-making. This is particularly important in a field where misconceptions or uneven understanding can slow progress, even when the underlying science is sound.
The organization’s structure, encompassing leading cosmetics and ingredient producers alongside trade and research groups as well as animal protection organizations, places it in a distinctive position to tackle these challenges. This broad range of viewpoints helps keep discussions balanced, well‑rooted, and oriented toward common objectives rather than limited agendas.
Headquartered in New York, ICCS continues to operate as a global initiative, reflecting the inherently international nature of cosmetics development and regulation. Products and ingredients often move across borders, making harmonization and mutual recognition of safety approaches increasingly important. Through its collaborative model, ICCS seeks to contribute to this harmonization, reducing duplication and fostering trust in animal-free science worldwide.
By confirming its 2026 Board officers, ICCS underscores stability while hinting at ongoing advancement, with its leadership team providing steady direction after a year marked by concrete achievements and the seasoned perspective needed to guide the next stage of transformation; as scientific innovation accelerates and regulatory expectations evolve, the organization’s role as a unifying hub and driving force for animal-free cosmetics safety science is set to become even more influential.
Ultimately, the importance of the 2026 Board elections rests not only on who is selected, but also on what their leadership conveys: a continued dedication to cooperation, scientific rigor, and the ethical progress of alternatives to animal testing. For ICCS and its stakeholders, the years ahead present a chance to turn ambition into enduring results, guiding the evolution of cosmetics safety in a manner that brings ethics, scientific excellence, and global public confidence into alignment.
